An electroencephalogram (EEG) recorded after sleep deprivation (SDEEG) in epilepsy patients often discloses epileptiform discharges (ED) when routine EEG (REEG) does not, but since sleep alone activates ED, activation during SDEEG may result merely from the induction of sleep. We retrospectively investigated whether SDEEG is useful when REEG containing wakefulness and sleep fails to show ED. Subjects were patients with definite or highly probable epilepsy whose REEG lacked ED and who later underwent SDEEG. All had wakefulness and at least stage II sleep during both REEG and SDEEG. Patients with ED on REEG were specifically excluded to avoid including patients with activation due merely to the occurrence of sleep. Patient and EEG characteristics were studied, including duration of wakefulness and each sleep stage and timing and characteristics of ED. Fifteen of 29 patients (52%) had activation on SDEEG; exclusively during wakefulness in 1, exclusively during sleep in 6 and in both wakefulness and sleep in 8. Activation rates were not significantly different between wakefulness (9, 60%), stage I (11, 74%) and stage II (11, 74%). EEG characteristics were similar for REEG and SDEEG, except that total EEG duration and stage II sleep were longer in SDEEG than in REEG, which did not influence activation by a logistic regression model (p > 0.05). We conclude that sleep deprivation activates ED independent of the activating effects of sleep and therefore is useful in evaluation of suspected epilepsy even when REEG contains sleep.
Summary:Purpose: Magnetic resonance imaging (MRI) is an essential diagnostic tool for the management of epilepsy at modern epilepsy clinics. This study was conducted to incorporate MRI features into the international classification of epilepsies and epilepsy syndromes (ICEES) proposed by the International League Against Epilepsy (ILAE).Methods: Three hundred consecutive patients newly registered in the Yonsei Epilepsy Clinic underwent stepwise classifications based on clinical features, clinical EEG, and clinical EEG-MRI correlations. The patients were required to have epilepsy and have undergone both EEG and MRI for inclusion in the study. Interictal epileptiform discharges (IEDs) in the EEG were divided into lobar, multilobar, and generalized. MRI lesions were divided into lobar and multilobar lesions. Lobar epilepsies (LEs) were divided into temporal, frontal, parietal, occipital, rolandic, temporoparietooccipital junctional, multilobar, and nonlocalized LEs.Results: Two hundred forty-nine patients satisfied the inclusion criteria. In the first-step diagnosis, 190 patients were classified as having localization-related epilepsy; 24 patients, generalized epilepsy; 34 patients, undetermined epilepsy; and one patient, a special syndrome. EEG revealed IEDs in 124 (50%) patients, and the second-step diagnosis changed the diagnostic categories of 79 (32%) patients. MRI detected lesions in 106 (43%) patients, and the third-step diagnosis changed the diagnostic categories of 30 (12%) patients. The nonspecific diagnostic categories of ICEES decreased from 49% to 37% and then to 29%, as diagnosis progressed from steps one to three. In cases of LE, MRI was superior to EEG in its clinical correlation. Additionally, the diagnostic precision in temporal lobe epilepsy was far better than that for other LEs.Conclusions: The impact of MRI on ICEES was only modest in terms of changing diagnostic categories, although MRI provided a structural substrate for epilepsy in 38% of patients with negative EEGs. In LE, MRI was as sensitive as EEG, and its clinical correlation was superior to that of EEG, which strongly supports the rationale of incorporating MRI into ICEES.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.